Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606229 | 0.75 | EPHX1 (0.39) | — | |
| SCHEMBL4599188 | 0.72 | EPHX1 (0.30) | — | |
| SCHEMBL8913111 | 0.70 | — | — | |
| SCHEMBL2916248 | 0.70 | — | — | |
| SCHEMBL5008463 | 0.69 | GABRR1 (0.38) | — | |
| SCHEMBL15542512 | 0.68 | SMN1; SMN2 (0.40) | DPP4DPP7 | |
| SCHEMBL15542099 | 0.68 | SMN1; SMN2 (0.40) | DPP4DPP7 | |
| SCHEMBL15542260 | 0.68 | SMN1; SMN2 (0.40) | DPP4DPP7 | |
| SCHEMBL15542390 | 0.68 | SMN1; SMN2 (0.40) | DPP4DPP7 | |
| SCHEMBL5781533 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| EP-1931336-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-06-18 | — | — | EP | claimed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | claimed |
| WO-2007038045-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | CNR2, CNR1, GPR18 | DPP4 3598/4885DPP7 3993/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | DPP4 583/4885DPP7 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.